Barclays Maintains Overweight on Progyny, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Negative 85.7%

Neg 85.7% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $29 to $23.